Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James F Blake

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Journal of Medicinal Chemistry|May 27, 2016
Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical DevelopmentJames F Blake, Michael Burkard, Jocelyn Chan, et al.
Journal of Medicinal Chemistry|September 1, 2012
Discovery and preclinical pharmacology of a selective ATP-competitive Akt inhibitor (GDC-0068) for the treatment of human tumorsJames F Blake, Rui Xu, Josef R Bencsik, et al.
ACS Medicinal Chemistry Letters|January 8, 2019
Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo ActivityJay B Fell, John P Fischer, Brian R Baer, et al.
Bioorganic & Medicinal Chemistry Letters|August 28, 2009
Non-nucleoside inhibitors of HCV polymerase NS5B. Part 4: structure-based design, synthesis, and biological evaluation of benzo[d]isothiazole-1,1-dioxidesJavier de Vicente, Robert T Hendricks, David B Smith, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 29, 2020
RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven MalignanciesBenjamin J Solomon, Lavinia Tan, Jessica J Lin, et al.
Bioorganic & Medicinal Chemistry Letters|August 25, 2009
Non-nucleoside inhibitors of HCV polymerase NS5B. Part 3: synthesis and optimization studies of benzothiazine-substituted tetramic acidsJavier de Vicente, Robert T Hendricks, David B Smith, et al.
Bioorganic & Medicinal Chemistry Letters|May 22, 2009
Non-nucleoside inhibitors of HCV polymerase NS5B. Part 2: Synthesis and structure-activity relationships of benzothiazine-substituted quinolinedionesJavier de Vicente, Robert T Hendricks, David B Smith, et al.
Cancer Discovery|June 5, 2017
A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid TumorsAlexander Drilon, Ramamoorthy Nagasubramanian, James F Blake, et al.
Journal of Medicinal Chemistry|April 7, 2020
Identification of the Clinical Development Candidate <b>MRTX849</b>, a Covalent KRAS<sup>G12C</sup> Inhibitor for the Treatment of CancerJay B Fell, John P Fischer, Brian R Baer, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Journal of Medicinal Chemistry|May 27, 2016
Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical DevelopmentJames F Blake, Michael Burkard, Jocelyn Chan, et al.
Journal of Medicinal Chemistry|September 1, 2012
Discovery and preclinical pharmacology of a selective ATP-competitive Akt inhibitor (GDC-0068) for the treatment of human tumorsJames F Blake, Rui Xu, Josef R Bencsik, et al.
ACS Medicinal Chemistry Letters|January 8, 2019
Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo ActivityJay B Fell, John P Fischer, Brian R Baer, et al.
Bioorganic & Medicinal Chemistry Letters|August 28, 2009
Non-nucleoside inhibitors of HCV polymerase NS5B. Part 4: structure-based design, synthesis, and biological evaluation of benzo[d]isothiazole-1,1-dioxidesJavier de Vicente, Robert T Hendricks, David B Smith, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 29, 2020
RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven MalignanciesBenjamin J Solomon, Lavinia Tan, Jessica J Lin, et al.
Bioorganic & Medicinal Chemistry Letters|August 25, 2009
Non-nucleoside inhibitors of HCV polymerase NS5B. Part 3: synthesis and optimization studies of benzothiazine-substituted tetramic acidsJavier de Vicente, Robert T Hendricks, David B Smith, et al.
Bioorganic & Medicinal Chemistry Letters|May 22, 2009
Non-nucleoside inhibitors of HCV polymerase NS5B. Part 2: Synthesis and structure-activity relationships of benzothiazine-substituted quinolinedionesJavier de Vicente, Robert T Hendricks, David B Smith, et al.
Cancer Discovery|June 5, 2017
A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid TumorsAlexander Drilon, Ramamoorthy Nagasubramanian, James F Blake, et al.
Journal of Medicinal Chemistry|April 7, 2020
Identification of the Clinical Development Candidate <b>MRTX849</b>, a Covalent KRAS<sup>G12C</sup> Inhibitor for the Treatment of CancerJay B Fell, John P Fischer, Brian R Baer, et al.
Pageof 3